MINI LONG - NOVO-NORDISK B | Market Closed - Börse Stuttgart 12:48:54 15/06/2024 am IST | ||
| 20.11 EUR | +0.75% |
|
| Current month | +9.83% | ||
| 1 month | +11.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 20.11 | +0.75% |
| 13/24/13 | 19.96 | -0.25% |
| 12/24/12 | 20.01 | +0.05% |
| 11/24/11 | 20 | -0.70% |
| 10/24/10 | 20.14 | +0.90% |
Delayed Quote Börse Stuttgart
Last update June 15, 2024 at 12:48 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MA61YW |
| ISIN | DE000MA61YW6 |
| Date issued | 23/04/2021 |
| Strike | 243.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.14 € |
|---|---|
| Lowest since issue | 0.193 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
